This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .
Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years.
Most children born small for gestational age ( SGA ) normalize their size through spontaneous catch-up growth within the first 2 yr after birth . Some SGA children fail to do so and maintain an abnormally short stature throughout childhood . We have previously reported that high dose GH treatment ( 66 or 100 microg/kg x day s.c . over 2 yr ; age at start , 2 - 8 yr ; n = 38 ) induces pronounced catch-up growth in short children born SGA , thereby normalizing their height and weight in childhood . Here , we report on the further prepubertal growth course of these children over the first 4 yr after withdrawal of early , high dose GH treatment . Of the 38 treated children , none developed precocious puberty , and 22 remained prepubertal . Mean age of the latter at start of GH was 4.4 yr , height was -3.7 SD score , and height after adjustment for midparental height was -2.9 SD score . Height increased by an average of 2.5 SD during the 2 yr of GH treatment and decreased by 0.4 and 0.3 SD , respectively , during the first and second year after GH withdrawal . Subsequently , when stature was not extremely short at the start ( mean adjusted height SD score , -2.7 ; n = 13 ) , no further GH treatment was given , and the adjusted height was stabilized around -1.0 SD score ; when stature was very short at the start ( mean adjusted height , -3.3 SD score ; n = 9 ) , a second course of GH treatment ( 66 microg/kg x day s.c . ) was initiated either 2 yr ( n = 5 ) or 3 yr ( n = 4 ) after initial GH withdrawal . This second course was associated with renewed catch-up growth and also result ed in a mean adjusted height of -1.0 SD score . In each subgroup , the pattern of the weight course paralleled that of the height course ; GH treatment was well tolerated . In conclusion , early , discontinuous , high dose GH treatment appears to be a safe and efficient option to normalize prepubertal height and weight in the majority of short SGA children . It remains to be examined whether the normalized stature will be maintained during pubertal development , either with or without further GH treatment
This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .